✅ Intellia's CRISPR therapy cuts swelling attacks by 98% in two-year study

Intellia Therapeutics has revealed that a single infusion of its experimental CRISPR therapy, called NTLA-2002, almost entirely eliminated swelling attacks in 10 people with hereditary angioedema. People with the genetic condition experience sudden inflammation that can cause disfiguring, painful and sometimes deadly swelling throughout the body. The new data from the Phase 1 trial follow a preliminary readout from last summer based on the first 16 weeks of observations in the study. In the new readout, which showed that the therapy continued to work after an average of 20 months, swelling attacks diminished by 98% in the 10-person group. One individual has remained attack-free for more than 26 months, and two people suffering frequent swelling attacks, 14 ...

Endpoints     Jun 02, 2024